New York, NY — Publication of data from three trials of pre-exposure prophylaxis (PrEP) for HIV – including the pivotal Partners PrEP trial – today in the New England Journal of Medicine provides strong evidence that HIV-negative men and women who consistently take a daily antiretroviral (ARV) pill (either TDF/FTC, brand name Truvada, or TDF, brand name Viread) can significantly reduce their risk of HIV infection.

The New England Journal of Medicine articles provide an in-depth review of safety, efficacy, adherence and risk behaviors in three trials whose primary results have been previously presented at scientific conferences and to the US Food and Drug Administration (FDA) as part of its ongoing review of Gilead Sciences’ application for a prevention indication for TDF/FTC for HIV-negative adults. Data from the three studies—including the FEM-PrEP study, which was stopped early for futility—underscore the need for adherence to the prescribed regimen of a once-daily pill to achieve protection from HIV infection.

“The evidence published today is clear: If you perceive yourself to be at risk, if you take your pill daily, and if you receive the drug as part of a comprehensive package of HIV prevention interventions and testing, oral PrEP can dramatically reduce your chances of becoming infected,” said Mitchell Warren, AVAC executive director.

“Daily oral PrEP is not a silver bullet or a stand-alone prevention solution. There are many strategies that work, including treatment for HIV-positive people, that will need to be brought to scale if we are to have the needed impact on new infections.”

“However, there will be men and women around the world for whom daily oral PrEP using TDF/FTC can be a life-saving prevention tool. Choice matters. For the millions of men and women who remain at risk for HIV worldwide, each new HIV prevention option offers additional hope that we will achieve the end of the epidemic.”

“Much of the momentum to roll out PrEP has focused on gay men in the United States, and PrEP will be an important option for many gay men. But, as these studies suggest, PrEP is also a viable and important option for heterosexual men and women in Africa and other parts of the world. We must ensure global access to this lifesaving intervention,” Warren added.

An action agenda for global PrEP implementation


AVAC is calling for immediate actions to ensure that PrEP can be made available to people at risk of HIV quickly, safely and through programs that maximize safety, use of comprehensive HIV prevention and impact on HIV infections.

AVAC’s recommendations include:

• Regulatory approval: The US FDA is considering approval of the drug TDF/FTC (marketed as Truvada) for daily PrEP among adults of risk of HIV infection. The FDA should approve Truvada for prevention. Regulatory agencies in other countries should quickly move to evaluate the evidence from these three trials among heterosexuals and the iPrEx trial among gay and bisexual men and transgender women and fast track regulatory decisions.

• Public health guidance: The US Centers for Disease Control and Prevention, the World Health Organization and other public health agencies should issue guidance on the appropriate use of daily TDF/FTC as PrEP in different populations and settings as soon as possible. Guidance is needed by providers and people at risk, and to help governments and funders set priorities for PrEP implementation.

• Demonstration projects: Real-world studies are urgently needed to answer important questions about how best to implement PrEP, including who can benefit most; how to provide PrEP safely and efficiently; how to integrate PrEP with other essential prevention methods such as condoms; and how to ensure high levels of adherence, which research has shown to be essential for PrEP to work. Currently, only a limited number of demonstration projects are planned or underway.

• Funding: As robust demonstration projects get underway, donors and governments should be quantifying resource needs for daily oral PrEP to be introduced as a sustained public health initiative for key populations. Funding for PrEP should not detract from other essential HIV prevention and treatment efforts. However, funders and governments should start now to quantify and identify resources for public health programming to bring daily oral PrEP using TDF/FTC to those who need it most.

• Additional research: Studies are currently underway to test PrEP in additional populations, including injecting drug users and to evaluate new drugs and less frequent PrEP dosing schedules. Trial sponsors, manufactures and regulatory agencies should stand ready to act on new data and further expand options for preventing HIV infection.

“PrEP, together with other prevention strategies that we have now and those still to be developed, could help to significantly reduce the global burden of HIV infections and could be a life-saving intervention for some men and women,” Warren added. “Multiple clinical trials have clearly shown that PrEP is safe and effective when used as prescribed. But clinical trials are not the ‘real world’—they are well-controlled environments designed to give clear data. We all must now act on the scientific evidence and translate it into real-world reductions in HIV infections. We simply cannot afford to dismiss any new options in the quest to end AIDS.”

For a PDF version of this press release, click here.

###

For more information about PrEP and the steps needed to make it available to people in need, visit www.prepwatch.org and www.avac.org/prep.

About AVAC: Founded in 1995, AVAC is a non-profit organization that uses education, policy analysis, advocacy and a network of global collaborations to accelerate the ethical development and global delivery of AIDS vaccines, male circumcision, microbicides, PrEP and other emerging HIV prevention options as part of a comprehensive response to the pandemic.

Contact: Kay Marshall, [email protected], +1-347-249-6375

New York, NY AVAC hails the recommendation by an FDA Advisory Committee that emtricitabine/tenofovir disoproxil fumarate (TDF/FTC or Truvada) be approved for use as pre-exposure prophylaxis (PrEP) among sexually active adult men and women. Citing the urgent need for new HIV prevention options to stem HIV infections, AVAC urges the FDA to issue an approval for all men and women at risk, and is calling on public health agencies, governments, advocates and funders to take action to ensure access to TDF/FTC as PrEP.

“This brings us closer to a watershed for global HIV prevention efforts,” said Mitchell Warren, executive director of AVAC. “PrEP, while not a panacea, will be an essential additional part to the world’s success in ending AIDS. For the millions of men and women who remain at risk for HIV worldwide, each new HIV prevention option offers additional hope that we will achieve the end of the epidemic.”

“The evidence from the clinical trials presented today is clear:  If you perceive yourself to be at risk, if you take your pill daily, and if you receive the drug as part of a comprehensive package of HIV prevention interventions and testing, oral PrEP can dramatically reduce your chances of becoming infected,” Warren said.

Noting that the FDA typically, but not always, follows its committees’ recommendations, Warren said, “With their support for approval, the FDA’s expert panel and its own scientists have followed the evidence.  We hope and expect that the agency will follow their sound advice.”

“As a young black gay HIV-negative man, I see that the current prevention options are not stemming HIV incidence in my community,” said Matthew Rose, policy chair of the Young Black Gay men’s Leadership Initiative and an AVAC PxROAR partner. “I know that a single drug or prevention strategy will not end this epidemic. But PrEP will give young gay black men tools that will allow them to manage their situation and make their own HIV prevention choices based on knowing all the options that exist.”

An action agenda for PrEP implementation
In anticipation of an FDA approval for TDF/FTC as PrEP, AVAC is calling for immediate actions to ensure that PrEP can be made available to people at risk of HIV quickly, safely and through programs that maximize safety, use of comprehensive HIV prevention and impact on HIV infections. These actions should take place in the US and in other countries that may take the FDA ruling as a positive signal for national introduction of TDF/FTC as PrEP.

“After decades of research, it’s thrilling that we can begin talking about access to a powerful new HIV prevention option,” Warren said. “Some funders and policymakers have been awaiting a signal from the FDA before launching demonstration projects or developing implementation plans.  The time for waiting is over. We need to get on with the work of setting priorities and rolling out PrEP to people who can benefit the most.”

AVAC’s recommendations include:

• Public health guidance:  The US Centers for Disease Control and Prevention, the World Health Organization and other public health agencies should issue guidance on the appropriate use of daily TDF/FTC as PrEP in different populations and settings as soon as possible. Guidance is needed by providers and people at risk, and to help governments and funders set priorities for PrEP implementation.
• Demonstration projects:  Real-world studies are urgently needed to answer important questions about how best to implement PrEP, including who can benefit most; how to provide PrEP safely and efficiently; how to integrate PrEP with other essential prevention methods such as condoms; and how to ensure high levels of adherence, which research has shown to be essential for PrEP to work. Currently, only a limited number of demonstration projects are planned or underway.
• Funding:  In addition to funding robust demonstration projects, donors and governments should be planning for significant investments in well-designed PrEP initiatives. Funding for PrEP should not detract from other essential HIV prevention and treatment efforts. However, funders should explore ways to repurpose funds that currently support lower-impact activities.
• Additional research:  Studies are currently underway to test PrEP in additional populations, including injecting drug users and to evaluate new drugs and less frequent PrEP dosing schedules. Trial sponsors, manufactures and the FDA should stand ready to act on new data and further expand options for preventing HIV infection.

“PrEP, together with other prevention strategies that we have now and those still to be developed, could help to significantly reduce the global burden of HIV infections and could be a life-saving intervention for some men and women, Warren added. “Multiple clinical trials have clearly shown that PrEP is safe and effective when used as prescribed. We all must now act on the scientific evidence and translate it into practice and impact. We simply cannot afford to dismiss any new options in the quest to end AIDS.”

For a PDF version of this press release, click here.

Contact:
Mitchell Warren, [email protected], +1-914-661-1536
Kay Marshall, [email protected], +1-347-249-6375

New York, NY — In public comments submitted this week, a group of 14 leading HIV/AIDS and health organizations stated their support for Food and Drug Administration (FDA) approval of emtricitabine/ tenofovir disoproxil fumarate (TDF/FTC or Truvada) as pre-exposure prophylaxis (PrEP) to prevent HIV infection in adult men and women. Their comments, submitted in advance of a May 10 FDA Advisory Committee meeting, pointed to compelling evidence on the efficacy of TDF/FTC as PrEP and highlighted the unique potential of this intervention to help slow the HIV epidemic in the US.

With PrEP, HIV-negative individuals who are at risk for HIV take anti-HIV medications in order to reduce their chances of becoming infected if exposed to the virus. At the May 10 hearing, the FDA will consider data from clinical trials showing that TDF/FTC reduced the risk of sexual transmission of HIV in populations including men who have sex with men (MSM) and heterosexual women and men.

“The US and international AIDS community overwhelmingly supports FDA’s priority review of this potentially game-changing new tool to prevent HIV,” said Mitchell Warren, executive director of AVAC. “The evidence is increasingly clear that daily PrEP can help reduce HIV risk in women and men who take it consistently as prescribed. While no single tool will be enough to stop the spread of HIV, PrEP could be a vital part of a comprehensive, global strategy to end the AIDS epidemic.”

Despite some progress in reducing HIV incidence using other available methods, approximately 50,000 people become newly infected with HIV every year in the United States, and 2.6 million people were newly infected with HIV worldwide in 2010. Globally, half of all people infected with HIV are women and girls. In the United States, HIV infection continues to take a disproportionate toll on African Americans and Latinos; MSM, including transgender individuals; and the poor. Driving down HIV infection rates is a primary objective of the U.S. National HIV/AIDS Strategy, and is at the core of global efforts to end the AIDS epidemic.

“Today’s HIV prevention tools, including condoms, remain as essential as ever, but it’s clear that they aren’t enough,” said Deborah Cohan of the Bay Area Perinatal AIDS Center. “If approved, PrEP would help address important gaps, including the need for women to have more ways to protect themselves without having to rely on their male partners.”

“Evaluation of new prevention tools is critical to reducing the devastating impact of HIV among Black Americans,” said Douglas Brooks, MSW, Senior Vice President of the Justice Resource Institute. “No single approach will be right for everyone, but PrEP could offer a much needed option for some. The benefits could be especially great for Black gay or bisexual men, who account for nearly one-quarter of new HIV infections in our nation today.”

Modeling studies have shown that widespread access to PrEP could reduce new HIV infections, and thus the scale of the global HIV epidemic, substantially around the world. The FDA’s decision on TDF/FTC as PrEP could help pave the way for global health funders and developing countries to step up their planning for implementation.

Evidence for PrEP: What the Science Tells Us
At the May hearing, an FDA Advisory Committee will consider data from a wide range of safety and efficacy studies, including two pivotal clinical trials of TDF/FTC as PrEP:

• The Partners PrEP trial, which found that daily TDF/FTC reduced HIV infections by 73 percent among heterosexual couples in Africa in which one partner was HIV infected and the other was not. Efficacy was 90 percent among those who adhered closely to their daily drug regimen.
• An international study called iPrEx found that daily use of the drugs reduced HIV infections by 42 percent among MSM, and by more than 90 percent among participants who took their medication consistently enough for the drug to be detected in their blood.

These studies demonstrate that PrEP was safe, with minimal side effects and no significant risk of drug resistance. These and other trials also indicate that effectiveness of TDF/FTC as PrEP depends greatly on individuals’ adherence to the PrEP regimen. In each trial, when adherence was low, there was low or no protection, pointing to the central importance of strategies to maximize adherence.

“If FDA approves PrEP, we’ll still have a lot of work to do, just as with any other new drug. We’ll have many questions to answer in order to use PrEP effectively to reduce HIV infections,” said David Munar, President and CEO of the AIDS Foundation of Chicago. “The essential next step will be to launch additional demonstration projects in a wide range of populations and settings. These real-world projects will help us understand how to achieve higher levels of adherence, how to best combine PrEP with other approaches, and which specific populations can benefit the most. While a handful of these real-world studies are now being planned, we need to pick up the pace.”

Summary of the Joint Comments to FDA
Based on the clinical trial results to date, the groups indicated their support for FDA approval of TDF/FTC among both men and women. They also highlighted evidence demonstrating the safety of TDF/FTC when used as PrEP, while urging the FDA to ensure appropriate labeling and post-marketing surveillance to ensure that any future safety concerns will be quickly identified and addressed. In addition, the groups also called for the full participation of communities most likely to benefit from PrEP in any future discussions about FDA-required educational/informational materials and programs to support safe use of TDF/FTC as PrEP.

The full text of the comments is available here. The comments were signed by the following organizations:

• AIDS Foundation of Chicago
• AIDS United
• AVAC: Global Advocacy for HIV Prevention
• Bay Area Perinatal AIDS Center
• Black AIDS Institute
• The Fenway Institute
• International Rectal Microbicide Advocates
• Justice Resource Institute
• National Black Gay Men’s Advocacy Coalition (NBGMAC)
• National Minority AIDS Council (NMAC)
• Project Inform
• San Francisco AIDS Foundation
• SHERO Empowerment Network
• SisterLove

Contact:
Mitchell Warren, [email protected], +1-914-661-1536
Kay Marshall, [email protected], +1-347-249-6375

###

New York, NY — AVAC strongly supports the California HIV/AIDS Research Program (CHRP) in launching new studies to evaluate the “real-world” use of oral pre-exposure prophylaxis (PrEP), a promising HIV prevention strategy recently shown to be effective in clinical trials.

The three CHRP-funded demonstration projects will provide vital information on how to implement recent research results to reduce HIV infections through the use of PrEP among HIV-negative people at high risk. Importantly, these studies will explore PrEP in the context of other new strategies to engage and retain HIV-infected individuals in care and treatment.

“PrEP, together with other prevention strategies, could help to significantly reduce HIV infections worldwide and could be a life-saving intervention for some men and women,” said Mitchell Warren, AVAC executive director. “Multiple clinical trials have clearly shown that PrEP is effective when used as prescribed. We now have an obligation to figure out how best to roll it out in the real world for people who need it and are able to use it, without delay.”

PrEP involves the use of daily anti-HIV medications by people who are uninfected but at high risk for HIV. Randomized-controlled trials that were closely overseen by independent ethical and regulatory bodies have shown that daily PrEP with a combination of the drugs tenofovir and emtricitabine (TDF/FTC, or Truvada) can reduce the risk of infection among gay men and other men who have sex with men (MSM), transgender women and heterosexual men and women. While other trials have shown no effect, the overall message is clear: adherence to the PrEP regimen is essential. Among trial participants who consistently took the PrEP pill, the risk of infection was reduced by more than 70 percent, while little or no benefit was seen when participants did not take the pill as prescribed.

“Finding ways to ensure that people who can benefit from PrEP are supported in taking the medication consistently has to be a top priority,” said Warren. “Real-world demonstration projects are the only way to test different approaches and find out what works. A year and a half after the first positive PrEP results, almost none are under way. This kind of delay is of severe concern to anyone interested in expanding the options for preventing HIV in some of the hardest-hit populations here in the US and worldwide.”

In addition to addressing adherence, demonstration projects are needed to answer questions about which populations benefit the most from PrEP and how to deliver it to them safely, effectively and at reasonable cost. They can also help determine the most effective ways to integrate PrEP with existing prevention strategies, such as male and female condoms, which remain essential to reducing HIV infections. AVAC and other advocates have called on governments and AIDS funders to launch an array of PrEP demonstration projects around the world, including the full range of populations that may benefit from the intervention.

“The California studies are smart to focus on gay men and transgender women, who are by far the most affected by HIV in the U.S. Now we need to do the same for other populations, especially the millions of women around the world who remain at risk. PrEP could help address the urgent need for new HIV prevention methods that women can control,” said Warren.

Warren also pointed to the upcoming U.S. Food and Drug Administration review of TDF/FTC as PrEP, saying, “The FDA’s review is a critical step in establishing access to PrEP and ensuring that accurate information is available to providers and potential users.” AVAC expects to be among a number of advocates submitting oral and written comments at a May 10 FDA Advisory Committee hearing.

“Ethics demand that we do everything we can to make proven HIV prevention options available to those who need them, when they need them. AIDS activists have a history of pushing researchers and regulators to make treatment available to people living with HIV as quickly as possible. People at risk of becoming infected deserve no less,” Warren said.

Contact:
Mitchell Warren, [email protected], +1-914-661-1536
Kay Marshall, [email protected], +1-347-249-6375

###

About AVAC: Founded in 1995, AVAC is a non-profit organization that uses education, policy analysis, advocacy and a network of global collaborations to accelerate the ethical development and global delivery of AIDS vaccines, male circumcision, microbicides, PrEP and other emerging HIV prevention options as part of a comprehensive response to the pandemic.